Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Feb 2023
Many fears arise in childhood. And the science is very clear. Observational fear learning is especially common in children who model their fear without parental support.
Read Full NewsHigher vs lower nighttime light exposure is associated with increased risk for obesity, hypertension, and dyslipidemia in patients with schizophrenia, a study suggests.
Transperineal 3D mapping biopsy may help select patients with low-risk prostate cancer who are most likely to fare well with active surveillance.
Many experts consider prostate cancer one of immunotherapy’s biggest disappointments. But a handful of patients don’t fit that narrative, and researchers are starting to uncover why.
1.
Pickleball program boosts health and wellness for cancer survivors, study finds
2.
O. A. J. Simpson passes away from cancer.
3.
Guidelines for cervical cancer screening and the risk of preterm birth in young women.
4.
In cancer patients taking immune checkpoint inhibitors, systematic vitamin D supplementation improves outcomes.
5.
What Comes After Cancer?
1.
Late Effects of Immunotherapy in Chronic Melanoma Survivorship with Repurposed Drugs
2.
Breaking Down the Different Types of Lymphoma: What You Need to Know
3.
HSC Failure in Fanconi Anemia: Mechanisms, Models, and Emerging Therapeutic Pathways
4.
Comprehensive Applications in Oncology and Quality Improvement
5.
Treating Methemoglobinemia: What You Need to Know Now!
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Evolution in Treatment and Diagnosis of Lung Cancer- An Initiative from Manipal Hospitals
2.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
3.
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
4.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge